Federated Hermes Inc. Raises Stake in Simulations Plus, Inc. $SLP

Federated Hermes Inc. boosted its stake in shares of Simulations Plus, Inc. (NASDAQ:SLP) by 90.7% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 126,742 shares of the technology company’s stock after purchasing an additional 60,283 shares during the period. Federated Hermes Inc.’s holdings in Simulations Plus were worth $1,910,000 as of its most recent filing with the SEC.

A number of other large investors have also added to or reduced their stakes in SLP. Kornitzer Capital Management Inc. KS boosted its stake in Simulations Plus by 121.7% in the third quarter. Kornitzer Capital Management Inc. KS now owns 51,000 shares of the technology company’s stock valued at $769,000 after acquiring an additional 28,000 shares during the last quarter. Stephens Investment Management Group LLC increased its stake in shares of Simulations Plus by 46.3% during the 3rd quarter. Stephens Investment Management Group LLC now owns 392,840 shares of the technology company’s stock worth $5,920,000 after purchasing an additional 124,264 shares during the last quarter. Tributary Capital Management LLC raised its holdings in shares of Simulations Plus by 214.7% in the 3rd quarter. Tributary Capital Management LLC now owns 1,136,980 shares of the technology company’s stock worth $17,134,000 after purchasing an additional 775,704 shares during the period. North Star Investment Management Corp. lifted its stake in Simulations Plus by 195.6% in the third quarter. North Star Investment Management Corp. now owns 168,130 shares of the technology company’s stock valued at $2,534,000 after purchasing an additional 111,255 shares during the last quarter. Finally, CWM LLC grew its holdings in Simulations Plus by 3,729.1% during the third quarter. CWM LLC now owns 2,106 shares of the technology company’s stock valued at $32,000 after purchasing an additional 2,051 shares during the period. Hedge funds and other institutional investors own 78.08% of the company’s stock.

Analyst Ratings Changes

Several analysts have issued reports on the company. KeyCorp restated a “sector weight” rating on shares of Simulations Plus in a research note on Wednesday, October 29th. Weiss Ratings restated a “sell (d-)” rating on shares of Simulations Plus in a research note on Wednesday, October 8th. BTIG Research downgraded shares of Simulations Plus from a “buy” rating to a “neutral” rating in a report on Thursday, December 18th. TD Cowen reiterated a “hold” rating on shares of Simulations Plus in a research note on Thursday, January 8th. Finally, Citigroup reissued a “market perform” rating on shares of Simulations Plus in a research report on Tuesday, January 6th. Three investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $25.00.

Simulations Plus Stock Down 3.8%

Shares of SLP opened at $14.82 on Thursday. Simulations Plus, Inc. has a twelve month low of $12.39 and a twelve month high of $37.67. The stock has a market cap of $298.62 million, a PE ratio of -4.63 and a beta of 1.12. The business’s 50-day moving average price is $18.94 and its 200-day moving average price is $16.56.

Simulations Plus (NASDAQ:SLP) last issued its quarterly earnings data on Thursday, January 8th. The technology company reported $0.13 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.05). The firm had revenue of $18.42 million for the quarter, compared to analysts’ expectations of $18.05 million. Simulations Plus had a negative net margin of 81.66% and a positive return on equity of 14.02%. During the same period in the prior year, the firm posted $0.17 EPS. Analysts expect that Simulations Plus, Inc. will post 1.09 earnings per share for the current fiscal year.

Simulations Plus Profile

Simulations Plus, Inc (NASDAQ: SLP) specializes in advanced modeling and simulation software tailored to the pharmaceutical, biotechnology and chemical industries. The company’s flagship products include ADMET Predictor, a quantitative structure-activity relationship (QSAR) tool for predicting absorption, distribution, metabolism, excretion and toxicity properties, and GastroPlus, a physiologically based pharmacokinetic (PBPK) modeling platform for simulating drug absorption and pharmacokinetics.